NEW YORK, July 18, 2026, 09:11 EDT – Iovance Biotherapeutics NASDAQ:IOVA shares rose 18% with investors focused on the upcoming sales test for Amtagvi.
Iovance Biotherapeutics, Inc. NASDAQ:IOVA gained approximately $344 million in equity value last week, representing 95.5% of its $360 million midpoint for full-year revenue guidance. U.S. markets were closed on Saturday. The company’s shares ended Friday at $5.00.
The development was related to the individual company. Shares of Iovance rose 18.2% since July 10. The SPDR S&P Biotech ETF (NYSEARCA:XBI) dropped 3.0%. The Nasdaq Biotechnology Index (INDEXNASDAQ:NBI) slipped 1.2%.
Friday’s gain was 7.3%. Trading volume hit 23.5 million shares, coming in 57% higher than the 65-day average. The company’s Friday announcement was related to employee stock options rather than operating performance.
| Measure | Latest reading | Comparison |
|---|---|---|
| Weekly stock return | +18.2% | XBI -3.0%; NBI -1.2% |
| Estimated equity value added | About $344 million | 95.5% of 2026 revenue midpoint |
| Second-quarter revenue guidance | $86 million-$88 million | 20%-23% higher than first quarter |
| Required second-half quarterly revenue | $95.8 million-$105.8 million | 10%-22% above second-quarter midpoint |
The equity value projection is provisional and is based on 446.5 million shares outstanding as of April 15. Sales figures are calculated using the second-quarter midpoint of $87 million. Market return comparisons use closing prices from July 10 and July 17.
The commercial test is now included in revenue. Iovance projected second-quarter product revenue between $86 million and $88 million, representing an increase of 20%-23% from the $71.43 million reported in the first quarter.
Based on the midpoint, full-year guidance implies $191.6 million-$211.6 million is needed in the second half, or $95.8 million-$105.8 million each quarter. This is 10%-22% higher than the second-quarter midpoint. The increase is still significant.
Management has positioned the effort as one of commercial delivery. “We are accelerating the adoption and commercial expansion for Amtagvi after record high demand,” interim CEO Frederick Vogt said in May. SEC
The company posted first-quarter revenue of $60.22 million from Amtagvi and $11.21 million from Proleukin. Management said there are now over 90 authorized treatment centers, with a goal to reach a minimum of 110 by year-end.
Gross margin reached 41% following maintenance and expansion outlays. Net loss declined 32% year-on-year, totaling $79.0 million. Cash, investments and restricted cash were $319.4 million. Management projects available funding will extend well into 2028.
A grant issued on Friday included 139,930 options for 17 recently hired, non-executive staff. The exercise price was set at $4.66, with vesting over three years. The options represent around 0.03% of the company’s April shares outstanding.
Risks continue to be significant. Iovance raised $98.5 million in the first quarter by selling 24.9 million shares through its at-the-market program. Additional sales may dilute existing shareholders. The filing added that product revenue might not result in positive operating cash flow in the coming year.
Iovance’s investor calendar does not show any scheduled event between July 20 and July 24. A market-data forecast suggests that second-quarter results could be released on August 6, though Iovance’s calendar has yet to confirm the date.
Shares rose first. The upcoming update will reveal if Amtagvi sales justify last week’s re-rating.
